The Market Institute joined dozens of free-market, taxpayer, and innovation-focused organizations in a February 12 coalition letter to Congress opposing efforts to codify a Most-Favored-Nation (MFN) prescription drug pricing model into law. In the letter, the coalition warned that MFN would not solve the real problem of foreign price controls. Read more…
In a recent article for RealClearHealth, Market Institute President Charles Sauer warns that the Trump administration’s new TrumpRx initiative may deliver lower drug prices in the short run—but at the cost of future medical innovation. Sauer explains that while the goal of lowering pharmaceutical prices is laudable, the method matters. Read more…
In a recent RealClearMarkets column, Charles Sauer examines the growing push to impose “most favored nation” (MFN) drug pricing through legislation expanding access to home infusion therapy—and explains why importing foreign-style price controls would ultimately hurt patients, not help them. Home infusion therapy allows millions of Americans with cancer, heart Read more…
In a recent turn of events, Senator Bernie Sanders has raised eyebrows by calling for the subpoena of two drug company CEOs, sparking both curiosity and concern. Market Institute President Charles Sauer’s new article in Townhall delves into Sanders’ unconventional tactics, questioning the wisdom of his confrontational approach to the Read more…
President Biden’s populist approach to healthcare reform, focusing on price controls, has stirred controversy in the pharmaceutical industry. A new article by Market Institute President Charles Sauer in The Hill highlights the potential consequences of this strategy, including drug shortages and stifled innovation. By exploring the lessons learned from Japan’s Read more…